Across TCGA pan-cancer cohorts, NHS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NHS data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NHS mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NHS expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where NHS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.678	0.325	.004	20	view →
LUAD	OS	Tertile	All	1.000	0.928	.017	6	view →
CCRCC	OS	Tertile	III,IV	0.978	0.259	.049	4	view →
GBM	OS	Median	All	0.304	0.503	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NHS tumor-vs-normal RNA expression · all NHS data types